These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 8732706)

  • 1. Increased tissue factor pathway inhibitor activity in IDDM patients with nephropathy.
    Yokoyama H; Myrup B; Rossing P; Ostergaard PB
    Diabetes Care; 1996 May; 19(5):441-5. PubMed ID: 8732706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased plasma apolipoprotein (a) levels in IDDM patients with diabetic nephropathy.
    Tarnow L; Rossing P; Nielsen FS; Hansen BV; Dyerberg J; Parving HH
    Diabetes Care; 1996 Dec; 19(12):1382-7. PubMed ID: 8941468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum sialic acid concentration is elevated in IDDM especially in early diabetic nephropathy.
    Yokoyama H; Jensen JS; Jensen T; Deckert T
    J Intern Med; 1995 May; 237(5):519-23. PubMed ID: 7738493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma homocysteine is related to albumin excretion rate in patients with diabetes mellitus: a new link between diabetic nephropathy and cardiovascular disease?
    Chico A; Pérez A; Córdoba A; Arcelús R; Carreras G; de Leiva A; González-Sastre F; Blanco-Vaca F
    Diabetologia; 1998 Jun; 41(6):684-93. PubMed ID: 9662051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased tissue factor pathway inhibitor (TFPI) and coagulation in patients with insulin-dependent diabetes mellitus.
    Leurs PB; van Oerle R; Wolffenbuttel BH; Hamulyak K
    Thromb Haemost; 1997 Mar; 77(3):472-6. PubMed ID: 9065996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. von Willebrand factor and development of diabetic nephropathy in IDDM.
    Stehouwer CD; Stroes ES; Hackeng WH; Mulder PG; Den Ottolander GJ
    Diabetes; 1991 Aug; 40(8):971-6. PubMed ID: 1907250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abnormalities in plasmas concentrations of lipoproteins and fibrinogen in type 1 (insulin-dependent) diabetic patients with increased urinary albumin excretion.
    Jensen T; Stender S; Deckert T
    Diabetologia; 1988 Mar; 31(3):142-5. PubMed ID: 3371576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hemorheology, plasma protein composition and von Willebrand factor in type I diabetic nephropathy.
    Zimmermann J; Schramm L; Wanner C; Mulzer E; Henrich HA; Langer R; Heidbreder E
    Clin Nephrol; 1996 Oct; 46(4):230-6. PubMed ID: 8905207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No effect of unfractioned or low molecular weight heparin treatment on markers of vascular wall and hemostatic function in incipient diabetic nephropathy.
    Myrup B; Jensen T; Gram J; Kluft C; Jespersen J; Deckert T
    Diabetes Care; 1997 Oct; 20(10):1615-9. PubMed ID: 9314645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A simple chromogenic substrate assay of tissue factor pathway inhibitor activity in plasma and serum.
    Berrettini M; Malaspina M; Parise P; Lucarelli G; Kisiel W; Nenci GG
    Am J Clin Pathol; 1995 Apr; 103(4):391-5. PubMed ID: 7726132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoclonal antibody specific for tissue factor pathway inhibitor-factor Xa complex: its characterization and application to plasmas from patients with disseminated intravascular coagulation and pre-disseminated intravascular coagulation.
    Ohkura N; Soe G; Kohno I; Kumeda K; Wada H; Kamikubo Y; Shiku H; Kato H
    Blood Coagul Fibrinolysis; 1999 Sep; 10(6):309-19. PubMed ID: 10493212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of aldose reductase inhibitor (tolrestat) on urinary albumin excretion rate and glomerular filtration rate in IDDM subjects with nephropathy.
    Passariello N; Sepe J; Marrazzo G; De Cicco A; Peluso A; Pisano MC; Sgambato S; Tesauro P; D'Onofrio F
    Diabetes Care; 1993 May; 16(5):789-95. PubMed ID: 8495620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of tissue factor pathway inhibitor (TFPI) in the HEPTEST assay and in an amidolytic anti factor Xa assay for LMW heparin.
    Kristensen HI; Ostergaard PB; Nordfang O; Abildgaard U; Lindahl AK
    Thromb Haemost; 1992 Sep; 68(3):310-4. PubMed ID: 1332210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue factor pathway inhibitor activity in patients with IDDM.
    Leurs PB; van Oerle R; Hamulyak K; Wolffenbuttel BH
    Diabetes; 1995 Jan; 44(1):80-4. PubMed ID: 7813818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between lipoprotein(a) and insulin-like growth factor I during puberty and the relationship to microalbuminuria in children and adolescents with IDDM.
    Rudberg S; Persson B
    Diabetes Care; 1995 Jul; 18(7):933-9. PubMed ID: 7555552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LDL subclasses in IDDM patients: relation to diabetic nephropathy.
    Lahdenperä S; Groop PH; Tilly-Kiesi M; Kuusi T; Elliott TG; Viberti GC; Taskinen MR
    Diabetologia; 1994 Jul; 37(7):681-8. PubMed ID: 7958539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between autonomic neuropathy, 24-h blood pressure profile, and nephropathy in normotensive IDDM patients.
    Spallone V; Gambardella S; Maiello MR; Barini A; Frontoni S; Menzinger G
    Diabetes Care; 1994 Jun; 17(6):578-84. PubMed ID: 8082528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protamine neutralization of the release of tissue factor pathway inhibitor activity by heparins.
    Harenberg J; Siegele M; Dempfle CE; Stehle G; Heene DL
    Thromb Haemost; 1993 Dec; 70(6):942-5. PubMed ID: 8165616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated serum total renin is insensitive in detecting incipient diabetic nephropathy.
    Matinlauri IH; Rönnemaa T; Koskinen PJ; Aalto MA; Vukari JS; Irjala KM
    Diabetes Care; 1995 Oct; 18(10):1357-61. PubMed ID: 8721937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of clinical diabetic nephropathy in IDDM patients. Alternatives to microalbuminuria?
    Mogensen CE
    Diabetes; 1990 Jul; 39(7):761-7. PubMed ID: 2191882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.